Dr Pippa Corrie - Publications

Wan JCM, Heider K, Gale D, Murphy S, Fisher E, Mouliere F, Ruiz-Valdepenas A, Santonja A, Morris J, Chandrananda D, Marshall A, Gill AB, Chan PY, Barker E, Young G, Cooper WN, Hudecova I, Marass F, Mair R, Brindle KM, Stewart GD, Abraham J, Caldas C, Rassl DM, Rintoul RC, Alifrangis C, Middleton MR, Gallagher FA, Parkinson C, Durrani A, McDermott U, Smith CG, Massie C, Corrie PG and Rosenfeld N. ctDNA monitoring using patient-specific sequencing and integration of variant reads. Sci Trans Med 2020; 12 (548) eaaz8084.

17 Jun 2020

Welsh SJ and Corrie PG. Biomarkers predicting for response and relapse with melanoma systemic therapy. Acta Dermato-Venereol 2020; 100: 300-8.

03 Jun 2020

Corrie PG, Qian W, Basu B, Valle JW, Falk S, lwuji C, Wasan H, Palmer D, Scott-Brown M, Wadsley J, Arif S, Bridgewater J, Propper D, Gillmore R, Gopinathan A, Skells R, Bundi R, Brais R, Dalchau K, Bax L, Chhabra A, Machin A, Dayim A, McAdam K, Cummins S, Wall L, Ellis R, Anthoney A, Evans J, Ma YT, Isherwood C, Neesse A, D Tuveson, Jodrell DI. Scheduling nab-paclitaxel combined with gemcitabine as first line treatment for metastatic pancreatic adenocarcinoma. Br J Cancer 2020; 122: 1760-68.

30 Apr 2020

PG Corrie, AM Moody, G Armstrong, S Nolasco, S Lao-Sirieix, L Bavister, AT Prevost, R Parker, R Sabes-Figuera, P McCrone, H Balsdon, K McKinnon, A Hounsell, B O’Sullivan, SIG Barclay. Is community treatment best? A randomised trial comparing delivery of cancer treatment in the hospital, home and GP surgery. Br J Cancer 2013; 109:1549-1555.

23 Aug 2019

Corrie P, Matrisian L, Poon JO. Pancreatic cancer – current landscape. Oncol Hematol Rev (US) 2019;15 (Suppl.1)

06 Sep 2019

Corrie PG, Marshall A, Nathan PD, Lorigan P , Gore M, Tahir S, Faust G, Kelly CG, Marples M, Danson SJ, Marshall M, Houston SJ, Board RE, Waterston AM, Nobes JP, Harries M, Kumar S, Goodman A, Dalgleish A, Martin-Clavijo A, Westwell S, Casasola R, Chao D, Maraveyas A, Patel P,Ottensmeier CH, Farrugia D, Humphreys A, Eccles B, Young G, Barker EO, Harman C, Weiss M, Myers KA, Chhabra A, Rodwell SH, Dunn JA, Middleton MR, on behalf of the AVAST-M Investigators. Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial. Annals Oncol 2018; 29: 1843-52.

01 Aug 2018

Lipplaa A, Fernandes R, Marshall A, Lorigan P, Dunn J, Myers KA, Barker E, Newton-Bishop J, Middleton MR, Corrie PG. 25-hydroxyvitamin D serum levels in patients with resected melanoma at high risk of recurrence. Br J Cancer 2018 119; 793-800.

23 Jul 2018

E Liniker, M Harrison, JMJ Weaver, N Agrawal, A Chhabra, V Kingshott, S Bailey, TGG Eisen, PG Corrie. Treatment costs associated with interventional cancer clinical trials conducted at a single UK institution over 2 years (2009-10). Br J Cancer 2013; 109: 2051-2057.

15 Oct 2013

Board R, Smittenaar R, Lawton S, Li H, Juwa G, Chao D, Corrie P. Metastatic melanoma patient outcomes since introduction of immune checkpoint inhibitors in England between 2014 and 2018. Int J Cancer 2020; doi.org/10.1002/ijc.33266.

24 Aug 2020

Rabbie R, Ferguson P, Wong K, Couturier D-L, Moran U, Turner C, Emanuel P, Haas K, Saunus JM, Davidson MR, Lakhani SR, Shivalingam B, Long GV, Parkinson C, Osman I, Scolyer RA, Corrie P, Adams DJ. The mutational landscape of melanoma brain metastases presenting as the first visceral site of recurrence. Br J Cancer 2020 (published online 07 October 2020)

07 Oct 2020